Zepbound Demonstrates Superior Weight Loss Over Wegovy in Head-to-Head Study – SURMOUNT-5 Phase 3b Clinical Trial Results
The results are based on the SURMOUNT-5 Phase 3b open-label clinical trial, in which the two incretin-based drugs were directly compared over a 72-week duration.
